Study of Combination Therapy With Dimebon and Donepezil (Aricept) in Patients With Alzheimer's Disease

Phase 2TerminatedNCT00704782

Medivation, Inc.50 enrolled

Overview

The purpose of this study is to assess the safety and efficacy of Dimebon in combination with donepezil (Aricept) in the treatment of Alzheimer's disease.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Alzheimer's Disease

Interventions

dimebonDRUG

Eligibility

Sex: ALLMin age: 50 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Alzheimer's disease * On donepezil (Aricept) * Caregiver who cares for the patient at least 5 days per week Exclusion Criteria: * Unstable medical illnesses or significant hepatic or renal disease * Other primary psychiatric or neurological disorders

Locations (4)

Xenoscience, Inc.

Phoenix, Arizona, United States

Banner Alzheimer's Institute

Phoenix, Arizona, United States

Barrow Neurological Institute

Phoenix, Arizona, United States

Sun Health Research Institute

Sun City, Arizona, United States

Outcomes

Primary Outcomes

To assess the safety of Dimebon in combination with donepezil (Aricept)

Time frame: week 6, 9, 12, 26 and every 13 weeks thereafter until study discontinuation

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.